Journal article

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease

Giulia Orlando, Philip J Law, Kimmo Palin, Sari Tuupanen, Alexandra Gylfe, Ulrika A Hanninen, Tatiana Cajuso, Tomas Tanskanen, Johanna Kondelin, Eevi Kaasinen, Antti-Pekka Sarin, Jaakko Kaprio, Johan G Eriksson, Harri Rissanen, Paul Knekt, Eero Pukkala, Pekka Jousilahti, Veikko Salomaa, Samuli Ripatti, Aarno Palotie Show all

HUMAN MOLECULAR GENETICS | OXFORD UNIV PRESS | Published : 2016

Grants

Awarded by Academy of Finland [Finnish Center of Excellence]


Awarded by European Research Council [ERC]


Awarded by Nordic Center of Excellence - NordForsk


Awarded by Kuopio University Hospital


Awarded by Academy of Finland


Awarded by Finnish Academy


Awarded by ENGAGE-European Network for Genetic and Genomic Epidemiology


Awarded by National Institute of Alcohol Abuse and Alcoholism


Awarded by Cancer Research UK


Awarded by European Union


Awarded by COST Action in the UK


Awarded by National Cancer Institute, National Institutes of Health


Awarded by CCFR centre: Australasian Colorectal Cancer Family Registry


Awarded by CCFR centre: USC Consortium Colorectal Cancer Family Registry


Awarded by CCFR centre: Mayo Clinic Cooperative Familial Registry for Colon Cancer Studies


Awarded by CCFR centre: Ontario Familial Colorectal Cancer Registry


Awarded by CCFR centre: Seattle Colorectal Cancer Family Registry


Awarded by CCFR centre: University of Hawaii Colorectal Cancer Family Registry


Awarded by Cancer Surveillance System of the Fred Hutchinson Cancer Research Center


Awarded by Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute


Awarded by National Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER)


Awarded by National Cancer Institute's Surveillance, Epidemiology and End Results Program


Awarded by Centers for Disease Control and Prevention's National Program of Cancer Registries



Awarded by Medical Research Council


Awarded by Tenovus Cancer Care


Funding Acknowledgements

In Finland, this work was supported by grants from the Academy of Finland [Finnish Center of Excellence Program 2012-2017, 250345], the Jane and Aatos Erkko Foundation, the Finnish Cancer Society [personal grant to K.P.], the European Research Council [ERC; 268648], the Sigrid Juselius Foundation, SYSCOL, the Nordic Information for Action eScience Center (NIASC), the Nordic Center of Excellence financed by NordForsk [project 62721, personal grant to K.P.] and State Research Funding of Kuopio University Hospital [B1401]. We acknowledge the computational resources provided by the ELIXIR node, hosted at the CSC-IT Center for Science, Finland, and funded by the Academy of Finland [grants 271642 and 263164], the Ministry of Education and Culture, Finland. V.S. was supported by the Finnish Academy [grant number 139635]. Sample collection and genotyping in the Finnish Twin Cohort has been supported by the Wellcome Trust Sanger Institute, ENGAGE-European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-2007 [grant agreement number 201413], the National Institute of Alcohol Abuse and Alcoholism [grants AA-12502 and AA-00145 to Richard J. Rose and K02AA018755 to Danielle M. Dick] and the Academy of Finland [grants 100499, 205585, 265240 and 263278 to J.K.].At the Institute of Cancer Research, this work was supported by Cancer Research UK [C1298/A8362-Bobby Moore Fund for Cancer Research UK]. Additional support was provided by the National Cancer Research Network and the NHS via the Biological Research Centre of the National Institute for Health Research at the Royal Marsden Hospital NHS Trust. In Edinburgh, the work was supported by Programme Grant funding from Cancer Research UK [C348/A12076]. In Oxford, additional funding was provided by the Oxford Comprehensive Biomedical Research Centre [to C.P. and I.P.M.T.] and the EU FP7 CHIBCHA grant [I.P.M.T.]. Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford was provided by grant [090532/Z/09/Z]. We are grateful to many colleagues within UK Clinical Genetics Departments (for CORGI) and to many collaborators who participated in the VICTOR and QUASAR2 trials. We also thank colleagues from the UK National Cancer Research Network (for NSCCG). Support from the European Union [FP7/207-2013, grant 258236] and FP7 collaborative project SYSCOL and COST Action in the UK is also acknowledged [BM1206]. The COIN and COIN-B trials were funded by Cancer Research UK and the Medical Research Council and were conducted with the support of the National Institute of Health Research Cancer Research Network. COIN and COIN-B translational studies were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the Kidani Trust, Cancer Research Wales and the National Institute for Social Care and Health Research Cancer Genetics Biomedical Research Unit (2011-2014) [all awarded to J.P.C.]. N.A.A., B.F.M. and S.M.W. were funded and supported by KFSHRC.The work of the Colon Cancer Family Registry (CCFR) was supported by from the National Cancer Institute [grant UM1 CA167551], National Institutes of Health and through cooperative agreements with the following CCFR centres: Australasian Colorectal Cancer Family Registry [U01 CA074778, U01/U24 CA097735], USC Consortium Colorectal Cancer Family Registry [U01/U24 CA074799], Mayo Clinic Cooperative Familial Registry for Colon Cancer Studies [U01/U24 CA074800], Ontario Familial Colorectal Cancer Registry [U01/U24 CA074783], Seattle Colorectal Cancer Family Registry [U01/U24 CA074794] and University of Hawaii Colorectal Cancer Family Registry [U01/U24 CA074806].The CCFR Illumina GWAS was supported by funding from the National Cancer Institute, National Institutes of Health [U01 CA122839 and R01 CA143237 to G.C.]. Seattle CCFR research was also supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center [Control Nos. N01-CN-67009 (1996-2003), N01-PC-35142 (2003-2010)] and the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute [Contract No. HHSN2612013000121 (2010-2017)] with additional support from the Fred Hutchinson Cancer Research Center. The collection of cancer incidence data for the State of Hawai'i used in this study was supported by the Hawai'i Department of Health as part of the statewide cancer reporting program mandated by Hawai'i Revised Statutes; the National Cancer Institute's Surveillance, Epidemiology and End Results Program (SEER) awarded to the University of Hawai'i [Control Nos. N01-PC-67001 (1996-2003), N01-PC-35137 (2003-2010), Contract Nos. HHSN26120100037C (2010-2013), HHSN261201300009I (2010-current)]. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of Hawai'i, Department of Health, the National Cancer Institute, SEER Program or their Contractors and Subcontractors is not intended nor should be inferred. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program [under contract HHSN261201000035C] awarded to the University of Southern California, and [contract HHSN261201000034C] awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement [U58DP003862-01] awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. Funding to pay the Open Access publication charges for this article was provided by COAF: Charity Open Access Fund.